Everest Medicines has received approval from China’s National Medical Products Administration (NMPA) for CARDAMYST® (etripamil) nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

PSVT is a condition involving sudden episodes of rapid and regular heart rhythm. Episodes can occur without warning and may cause palpitations, shortness of breath, chest discomfort, dizziness and light-headedness. An estimated 3 million to 6 million people in China are affected by the condition.

CARDAMYST was approved by the US Food and Drug Administration (FDA) in December 2025. It is currently being developed in Phase III trials for atrial fibrillation with rapid ventricular response (AFib-RVR), following positive Phase II results.

Etripamil was developed by Milestone Pharmaceuticals. In March 2026, Everest Medicines entered into an asset purchase agreement with CORXEL Pharmaceuticals to acquire the rights to develop, manufacture and commercialise CARDAMYST in Greater China.

The approval marks Everest Medicines’ first cardiovascular therapy approved in China. CARDAMYST is a rapid-acting calcium channel blocker administered through a nasal spray and is designed for patient use when a PSVT episode occurs.

The approval was supported by results from the global Phase III RAPID trial and the China Phase III JX02002 study. Both trials met their primary endpoints. In the RAPID trial, 64% of patients who self-administered etripamil achieved conversion to sinus rhythm within 30 minutes, compared with 31% of those receiving placebo (HR 2.62; p<0.001). Results from the trial were published in The Lancet in 2023.

In the JX02002 study, 84 patients received etripamil and 84 received placebo. A greater proportion of patients in the etripamil group achieved conversion to sinus rhythm within 30 minutes, with a reported hazard ratio of 3.002 (p=0.0005). The treatment was generally well tolerated, with most adverse events reported as mild.

The company estimates that CARDAMYST could potentially address the needs of more than 12 million patients in China across PSVT and AFib-RVR indications.

 

Source: everestmedicines.com

Report Abuse